NCT06907251Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 192 (estimated)
- First submitted
- 31 Mar 2025
- Start date
- 1 Dec 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06907251
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 192
- From 1 Dec 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior heart failure
- Weight loss treatment with glucagon-like peptide-1 receptor agonists (e.g. liraglutide, semaglutide)
Other illness
- History of diabetes
- Known history of allergy or hypersensitivity to dapagliflozin
- Exclusion for optional MRI portion of the protocol:
- \- Any contraindication to MRI
Lab values
- Severe renal impairment (eGFR\<30mL/min1.73m2)
Other
- Pregnancy or planned pregnancy in the next 12 months. We will ask WOCBP about the possibility of pregnancy at the time of screening and if so, then pregnancy testing will be offered. If testing is declined in this instance, then they will be excluded from the study.
- Women who are breastfeeding
Who the study is looking for
- 18 years of age or older and willing and able to provide informed consent
- Patients with a history of positive COVID-19 test (polymerase chain reaction or rapid test) or have been diagnosed with COVID-19 by a health care provider.
- New or persistent symptoms at least 12 weeks from infection and present for at least 8 weeks that is not explained by an alternative diagnosis (64).
- Women of childbearing potential (WOCBP) who, if sexually active, are willing to use to use at least one highly effective methods of contraception throughout the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.